Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;24(4):478-494.
doi: 10.2174/1566524023666230509161645.

The mTOR Signaling Pathway and mTOR Inhibitors in Cancer: Next-generation Inhibitors and Approaches

Murat Ihlamur  1   2 , Busra Akgul  1 , Yağmur Zengin  3 , Şenay Vural Korkut  4 , Kübra Kelleci  1   5 , Emrah Şefik Abamor  1
Affiliations
Review

The mTOR Signaling Pathway and mTOR Inhibitors in Cancer: Next-generation Inhibitors and Approaches

Murat Ihlamur et al. Curr Mol Med. 2024.

Abstract

mTOR is a serine/threonine kinase that plays various roles in cell growth, proliferation, and metabolism. mTOR signaling in cancer becomes irregular. Therefore, drugs targeting mTOR have been developed. Although mTOR inhibitors rapamycin and rapamycin rapalogs (everolimus, rapamycin, temsirolimus, deforolimus, etc.) and new generation mTOR inhibitors (Rapalink, Dual PI3K/mTOR inhibitors, etc.) are used in cancer treatments, mTOR resistance mechanisms may inhibit the efficacy of these drugs. Therefore, new inhibition approaches are developed. Although these new inhibition approaches have not been widely investigated in cancer treatment, the use of nanoparticles has been evaluated as a new treatment option in a few types of cancer. This review outlines the functions of mTOR in the cancer process, its resistance mechanisms, and the efficiency of mTOR inhibitors in cancer treatment. Furthermore, it discusses the next-generation mTOR inhibitors and inhibition strategies created using nanoparticles. Since mTOR resistance mechanisms prevent the effects of mTOR inhibitors used in cancer treatments, new inhibition strategies should be developed. Inhibition approaches are created using nanoparticles, and one of them offers a promising treatment option with evidence supporting its effectiveness.

Keywords: approaches.; cancer; mTOR; mTOR inhibitor; nanoparticles; next-generation inhibitors; resistance mechanisms.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Bray F.; Ferlay J.; Soerjomataram I.; Siegel R.L.; Torre L.A.; Jemal A.; Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018,68(6),394-424 - DOI - PubMed
    1. Cree I.A.; Cancer biology. Methods Mol Biol 2011,731,1-11 - DOI - PubMed
    1. Sever R.; Brugge J.S.; Signal transduction in cancer. Cold Spring Harb Perspect Med 2015,5(4),a006098 - DOI - PubMed
    1. Panda M.; Biswal B.K.; Cell signaling and cancer: A mechanistic insight into drug resistance. Mol Biol Rep 2019,46(5),5645-5659 - DOI - PubMed
    1. Manning G.; Whyte D.B.; Martinez R.; Hunter T.; Sudarsanam S.; The protein kinase complement of the human genome. Science 2002,298(5600),1912-1934 - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources

-